IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v2y2018i4d10.1007_s41669-017-0062-z.html
   My bibliography  Save this article

The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study

Author

Listed:
  • Claudio Jommi

    (Università del Piemonte Orientale
    SDA School of Management Bocconi)

  • Patrizio Armeni

    (SDA School of Management Bocconi)

  • Margherita Battista

    (Università del Piemonte Orientale)

  • Paolo Procolo

    (Università del Piemonte Orientale)

  • Giuseppe Conte

    (Second University of Naples)

  • Claudio Ronco

    (San Bortolo Hospital)

  • Mario Cozzolino

    (University of Milan)

  • Anna Maria Costanzo

    (Abbvie Srl, Campoverde di Aprilia)

  • Umberto Luzio Paparatti

    (Abbvie Srl, Campoverde di Aprilia)

  • Gabriella Concas

    (Struttura Complessa Territoriale Nefrologia e Dialisi-ASL 8 Cagliari)

  • Giuseppe Remuzzi

    (IRCCS, Istituto di Ricerche Farmacologiche Mario Negri)

Abstract

Background Chronic kidney disease (CKD) is an important public health problem. Most of the evidence on its costs relates to patients receiving dialysis or kidney transplants, which shows that, in these phases, CKD poses a high burden to payers. Less evidence is available on the costs of the predialytic phase. Objective The aim of this study was to estimate the annual cost of patients with CKD not receiving dialysis treatment, using the Italian healthcare system perspective and a prospective approach. Methods A 3-year observational study (December 2010–September 2014) was carried out to collect data on resource consumption for 864 patients with CKD. Costs were estimated for both patients who completed the follow-up and dropouts. Results The mean annual total (healthcare) cost per patient equalled €2723 (95% confidence interval 2463.0–2983.3). Disease severity (higher CKD stage), multiple comorbidities, dropout status and belonging to the southern region are predictive of higher costs. Pharmaceuticals, hospitalisation, and outpatient services account for 71.5, 18.8 and 9.7% of total healthcare expenditure, respectively. Recent estimates of Italian costs of patients receiving dialysis are nine times the unit costs of CKD for patients estimated in this study. Unit costs at stage 5 CKD (the highest level of severity) equals 4.7 times the costs for patients at stage 1 CKD. Conclusion Despite its limitations, this study provides further evidence on the opportunity to invest in the first phases of CKD to avoid progression and an increase in healthcare costs.

Suggested Citation

  • Claudio Jommi & Patrizio Armeni & Margherita Battista & Paolo Procolo & Giuseppe Conte & Claudio Ronco & Mario Cozzolino & Anna Maria Costanzo & Umberto Luzio Paparatti & Gabriella Concas & Giuseppe R, 2018. "The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study," PharmacoEconomics - Open, Springer, vol. 2(4), pages 459-467, December.
    • Handle: RePEc:spr:pharmo:v:2:y:2018:i:4:d:10.1007_s41669-017-0062-z
    DOI: 10.1007/s41669-017-0062-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-017-0062-z
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-017-0062-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Giuseppe Pontoriero & Pietro Pozzoni & Lucia Vecchio & Francesco Locatelli, 2007. "International Study of Health Care Organization and Financing for renal replacement therapy in Italy: an evolving reality," International Journal of Health Economics and Management, Springer, vol. 7(2), pages 201-215, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sarah Elshahat & Paul Cockwell & Alexander P Maxwell & Matthew Griffin & Timothy O’Brien & Ciaran O’Neill, 2020. "The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review," PLOS ONE, Public Library of Science, vol. 15(3), pages 1-19, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Björn Wikström & Michael Fored & Margaret Eichleay & Stefan Jacobson, 2007. "The financing and organization of medical care for patients with end-stage renal disease in Sweden," International Journal of Health Economics and Management, Springer, vol. 7(4), pages 269-281, December.
    2. Avi Dor & Mark Pauly & Margaret Eichleay & Philip Held, 2007. "End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF)," International Journal of Health Economics and Management, Springer, vol. 7(2), pages 73-111, September.
    3. José Luño, 2007. "The organization and financing of end-stage renal disease in Spain," International Journal of Health Economics and Management, Springer, vol. 7(4), pages 253-267, December.
    4. Isabelle Durand-Zaleski & Christian Combe & Philippe Lang, 2007. "International Study of Health Care Organization and Financing for end-stage renal disease in France," International Journal of Health Economics and Management, Springer, vol. 7(2), pages 171-183, September.
    5. Werner Kleophas & Helmut Reichel, 2007. "International study of health care organization and financing: development of renal replacement therapy in Germany," International Journal of Health Economics and Management, Springer, vol. 7(2), pages 185-200, September.
    6. Avi Dor & Mark V. Pauly & Margaret A. Eichleay & Philip J. Held, 2007. "End-stage Renal Disease and Economic Incentives: The International Study of Health Care Organization and Financing," NBER Working Papers 13125, National Bureau of Economic Research, Inc.
    7. Anne-Line Couillerot-Peyrondet & Cléa Sambuc & Yoël Sainsaulieu & Cécile Couchoud & Isabelle Bongiovanni-Delarozière, 2017. "A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(4), pages 459-469, May.
    8. Wim Biesen & Norbert Lameire & Patrick Peeters & Raymond Vanholder, 2007. "Belgium’s mixed private/public health care system and its impact on the cost of end-stage renal disease," International Journal of Health Economics and Management, Springer, vol. 7(2), pages 133-148, September.
    9. Katherine Rojahn & Suzanne Laplante & James Sloand & Claire Main & Aftab Ibrahim & Janet Wild & Nicky Sturt & Thelga Areteou & K Ian Johnson, 2016. "Remote Monitoring of Chronic Diseases: A Landscape Assessment of Policies in Four European Countries," PLOS ONE, Public Library of Science, vol. 11(5), pages 1-15, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:2:y:2018:i:4:d:10.1007_s41669-017-0062-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.